J&J Doing Damage Control Following Reuters Report On Asbestos ‘Lurking’ In Johnson’s Powder

J&J shares are down nearly 12% since Reuters reported Dec. 14 that the firm has known for decades about toxic asbestos in its Johnson’s Baby Powder talc. The news outlet’s probe turned up nothing that hasn’t been raised by plaintiff attorneys, but throws the central issues of contention into high relief for its global audience.

Asbestos

Johnson & Johnson suffered a major setback Dec. 14 in its battle to defend the safety of Johnson’s Baby Powder on the global PR front – in addition to the courts – in the form of a Reuters report suggesting the firm has been concealing asbestos-tainted talc risks from the public for decades.

The firm’s stock plummeted following the report’s publication and remains down roughly 12% as of mid-morning trading Dec. 19.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal

‘Off-Label’ Beauty Hacks: Navigating the Risks of Consumer-Driven Innovation

 
• By 

Guest authors Rachel Raphael, partner at Morgan, Lewis & Bockius, LLP and associates at the firm, Elizabeth Bresnahan and Kathryn Ignash, advise beauty companies on how to navigate the legal risks associated with consumers ‘off-label’ beauty hacks.

Supreme Court 1935 Ruling Limiting Executive Authority On Appointments ‘Unravels’ Today – DoJ

 

In complaint and response to motion to dismiss, Rebecca Kelly Slaughter’s and Alvaro Bedoya’s attorneys elaborate on Supreme Court ‘s 1935 decision, Humphrey’s Executor v. US. Administration attorneys, though, contend the ruling isn’t relevant to the current FTC.

Estee Lauder Faces Securities Fraud Suit After District Court Denies Motion To Dismiss

 

A federal judge in the Southern District of New York denied Estee Lauder’s motion to dismiss a securities fraud lawsuit filed by shareholders who said the company concealed its reliance on a gray market retail revenue stream, which ultimately caused sales and the stock price to plunge.

Uncertainty Abounds With SEC Climate Reporting Rule Tied Up In Courts

 
• By 

Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.

More from Policy & Regulation

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 

FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By 

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.